DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-200-0200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.03 billion
Profitability
Miscellaneous
Employees2,800
Next Earnings Date11/6/2019 (Confirmed)
OptionableOptionable
DexCom (NASDAQ:DXCM) Frequently Asked Questions
What is DexCom's stock symbol?
DexCom trades on the NASDAQ under the ticker symbol "DXCM."
How were DexCom's earnings last quarter?
DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings data on Wednesday, July, 31st. The medical device company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.07. The medical device company earned $336.40 million during the quarter, compared to analysts' expectations of $304.40 million. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The firm's revenue for the quarter was up 38.7% on a year-over-year basis. During the same period last year, the firm earned ($0.10) EPS. View DexCom's Earnings History.
When is DexCom's next earnings date?
How can I listen to DexCom's earnings call?
DexCom will be holding an earnings conference call on Wednesday, November 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has DexCom issued on next quarter's earnings?
DexCom issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.325-1.375 billion, compared to the consensus revenue estimate of $1.29 billion.
What price target have analysts set for DXCM?
15 Wall Street analysts have issued 12 month price targets for DexCom's shares. Their forecasts range from $125.00 to $195.00. On average, they expect DexCom's share price to reach $171.93 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price. View Analyst Price Targets for DexCom.
What is the consensus analysts' recommendation for DexCom?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.
What are Wall Street analysts saying about DexCom stock?
Here are some recent quotes from research analysts about DexCom stock:
- 1. According to Zacks Investment Research, "Shares of the company have outperformed the industry in a year's time. Strong contributions from the Sensor and Transmitter segments have been key catalysts. Further, solid guidance instills optimism in the stock. The glucose monitoring market presents significant commercial opportunity for DexCom. Opportunities in alternative markets such as the non-intensive diabetes management space, hospital, gestational, pre-diabetes and obesity are likely to provide DexCom a competitive edge in the MedTech space. Meanwhile, cutthroat competition in the market for blood & glucose monitoring devices remains a headwind. With respect to quarterly results, DexCom exited the second quarter on a strong note, wherein both the top and bottom line beat the Zacks Consensus Estimate." (8/12/2019)
- 2. Northland Securities analysts commented, "We present here a comparative assessment of 2.0 data readouts. Our global view is….we love Dexcom, but believe the story is going to be pressured on all fronts….top-line growth, margins, and market share. If this data is representative of the FDA submission (or part thereof), there is no doubt that Libre 2.0 will get an i" designation." (6/6/2019)
Has DexCom been receiving favorable news coverage?
News articles about DXCM stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. DexCom earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for DexCom.
Who are some of DexCom's key competitors?
Some companies that are related to DexCom include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM) and NuVasive (NUVA).
What other stocks do shareholders of DexCom own?
Who are DexCom's key executives?
DexCom's management team includes the folowing people:
- Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
- Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
- Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
- Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
- Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)
Who are DexCom's major shareholders?
DexCom's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.33%), Peregrine Capital Management LLC (0.32%), Robeco Institutional Asset Management B.V. (0.20%), Envestnet Asset Management Inc. (0.06%), Silverleafe Capital Partners LLC (0.03%) and Gateway Investment Advisers LLC (0.02%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.
Which major investors are selling DexCom stock?
DXCM stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Gateway Investment Advisers LLC, CenturyLink Investment Management Co, Zeke Capital Advisors LLC, Stephens Inc. AR, Navellier & Associates Inc and Landsberg Bennett & Dubbaneh LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.
Which major investors are buying DexCom stock?
DXCM stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Silverleafe Capital Partners LLC, Envestnet Asset Management Inc., Stephens Investment Management Group LLC, Avitas Wealth Management LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, Oakbrook Investments LLC and CIBC Private Wealth Group LLC. View Insider Buying and Selling for DexCom.
How do I buy shares of DexCom?
Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is DexCom's stock price today?
One share of DXCM stock can currently be purchased for approximately $156.92.
How big of a company is DexCom?
DexCom has a market capitalization of $14.31 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.
What is DexCom's official website?
How can I contact DexCom?
DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]
MarketBeat Community Rating for DexCom (NASDAQ DXCM)
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
